中国百日咳血清流行病学:基于人群的横断面研究
结果显示,0-6岁儿童抗PT IgG几何平均浓度(GMC)为5.99 IU/ml(95%CI 5.39-6.67),随基础免疫和加强接种升高后持续下降,6岁时降至最低点3.72 IU/ml(95%CI 2.91-4.77)。>6岁人群GMC为5.67 IU/ml(95%CI 5.36-6.00),血清阳性率6.7%(95%CI 5.5-7.9),近期感染率1.2%(95%CI 0.7-1.7),血清阳性率从6岁上升,9岁达峰值10.3%(95%CI 0.7-19.8)。结论支持在学龄前增加百日咳疫苗加强剂次。
要点
- 接种百日咳疫苗可升高抗PT IgG,但免疫力随时间衰减。
- 6岁时抗PT IgG GMC降至最低点3.72 IU/ml(95%CI 2.91-4.77)。
- >6岁人群血清阳性率6.7%,近期感染率1.2%,9岁阳性率峰值10.3%。
核心结论
- 百日咳疫苗接种可升高抗PT IgG,但免疫应答随时间衰减。
- 血清学估计的感染率从学龄期开始上升,约9岁达峰值。
- 结果支持在学龄前增加百日咳疫苗加强剂次。
研究设计与样本
- 采用ELISA检测血清抗百日咳毒素IgG抗体(anti-PT IgG)。
- 计算抗PT IgG浓度(GMC)、血清阳性率(GMC ≥ 40 IU/ml)和近期感染率(GMC > 100 IU/ml)。
- ≤2岁受试者按疫苗接种程序间隔分层,≤6岁受试者按所用疫苗(国产DTaP或DTaP-IPV//PRP ~ T(Pentaxim,SP))分层。
主要发现
- 0-6岁儿童抗PT IgG GMC为5.99 IU/ml(95%CI 5.39-6.67)。
- GMC随基础免疫系列(4-6月龄)和幼儿加强针(18-23月龄)升高,此后持续下降,6岁时降至最低点3.72 IU/ml(95%CI 2.91-4.77)。
- 接种DTaP-IPV/PRP ~ T者GMC明显高于接种DTaP者。
- >6岁人群GMC为5.67 IU/ml(95%CI 5.36-6.00),血清阳性率6.7%(95%CI 5.5-7.9),近期感染率1.2%(95%CI 0.7-1.7)。
- 血清阳性率从6岁上升,9岁达峰值10.3%(95%CI 0.7-19.8)。
关键数值与推荐
- 血清阳性判定标准:抗PT IgG GMC ≥ 40 IU/ml。
- 近期感染判定标准:抗PT IgG GMC > 100 IU/ml。
- 0-6岁儿童抗PT IgG GMC为5.99 IU/ml(95%CI 5.39-6.67),6岁时最低点3.72 IU/ml(95%CI 2.91-4.77)。
- >6岁人群血清阳性率6.7%(95%CI 5.5-7.9),近期感染率1.2%(95%CI 0.7-1.7),9岁阳性率峰值10.3%(95%CI 0.7-19.8)。
临床怎么用
- 监测疫苗接种后抗PT IgG水平变化,识别免疫衰减关键年龄点。
- 考虑在学龄前(约6岁)增加百日咳疫苗加强剂次以维持免疫保护。
- 不同疫苗产品免疫应答存在差异,接种DTaP-IPV/PRP ~ T者GMC更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite high pertussis vaccination coverage and significant decrease of pertussis since the adoption of the Expanded Programme on Immunization (1978), increased pertussis incidence has been reported in China from 2013 to 2017. This study aimed at evaluating the immune response to pertussis among vaccinated children and beyond in China. METHODS: The study recruited 2 144 healthy subjects. Serum IgG antibodies against pertussis toxin (anti-PT IgG) were measured by ELISA. Anti-PT IgG concentration (GMC), seropositivity rate (GMC ≥ 40 IU/ml), and recent infection rate (GMC > 100 IU/ml) were calculated. Participants ≤ 2 years-old were further stratified by vaccination schedule intervals and participants ≤ 6 years-old by vaccine used (Domestic DTaP or DTaP-IPV//PRP ~ T (Pentaxim, SP)). RESULTS: Among 0-6-year-olds, the anti-PT IgG GMC was 5.99 IU/ml (95%CI 5.39-6.67). The GMC increased in accordance with the primary vaccination series (4-6 months) and the toddler booster (18-23 months), and continuously declined thereafter to its nadir at 6 years-old [3.72 IU/ml (95%CI 2.91-4.77)]. GMCs were markedly higher in those vaccinated with DTaP-IPV/PRP ~ T compared to DTaP. In individuals > 6 years-old, the GMC was 5.67 IU/ml (95%CI 5.36-6.00), the seropositivity rate was 6.7% (95%CI 5.5-7.9) and the recent infection rate was 1.2% (95%CI 0.7-1.7). The seropositivity rates increased from 6 years-old and peaked at 9 years-old (10.3% [95%CI 0.7-19.8]). CONCLUSIONS: Vaccination against pertussis increases anti-PT IgG, but wanes over time. The sero-estimated infection rates increase from school age and peak at about 9 years-old. These results support the addition of a booster of pertussis vaccine at preschool age.
引用
- Zhang Z, Pan J, Chen M, et al. Seroepidemiology of pertussis in China: A population-based, cross-sectional study. Vaccine. 2021. PMID: 33642160. doi:10.1016/j.vaccine.2021.02.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。